Drug intelligence / Profile preview

WTX202

Development stage: Preclinical
Lead developer: Wntrix
Modality: Small Molecules

Overview

WTX202 is a preclinical-stage small molecule inhibitor being developed by Wntrix for the treatment of liver cancer (hepatocellular carcinoma). The drug is designed to target the Wnt signaling pathway, which is frequently dysregulated in liver malignancies and plays a critical role in tumor initiation, progression, and the maintenance of cancer stem cells. Wntrix specializes in the discovery of novel compounds that modulate Wnt signaling to address unmet needs in oncology. As of 2024, WTX202 remains in the preclinical phase of development.

Beyond the preview

Go deeper on WTX202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX202.

Explore the full profile